News

Addrenex has formed a partnership with Dream Pharma to advance the treatment of adrenergic-related conditions worldwide. Addrenex has licensed the right to manufacture, market and sell its lead

Amarillo Biosciences has completed full enrollment in a phase 2 clinical study of its oral interferon product at the University of Western Australia, located in Perth. Reportedly, a

In light of the foregoing, the directors of the Corporation have resigned. The implications for creditors and other stakeholders of the Corporation are not known at this time

FairWarning has announced a certification program that empowers value-added resellers (VARs) and professional service organizations with the ability to deploy, service and resell FairWarning privacy monitoring solutions. The

DrFirst has announced partnership with Maine’s health information network HealthInfoNet. DrFirst believes that connectivity in the medical industry can have a profound influence in providing the highest levels

M2SYS Technology has announced that GHG Corporation has chosen to provide their customers with M2SYS’ Bio-SnapON biometric software solution.   Bio-SnapON allows GHG to instantly add biometric recognition

Chemizon has reported that Takeda will continue, and further expand its current research collaboration that utilizes Chemizon’s Discovery Platform. The expansion will be effective beginning the 1st of

Synta Pharmaceuticals has reported a net loss of $8.5 million, or $0.25 per basic and diluted share, for the second quarter in 2009, as compared to a net

Nile has reported the dosing of its first patient in a phase 2 clinical study of its lead product, CD-NP, for the treatment of acute heart failure. The